Literature DB >> 24909585

Vitamin K deficiency evaluated by serum levels of undercarboxylated osteocalcin in patients with anorexia nervosa with bone loss.

Ayako Urano1, Mari Hotta2, Rina Ohwada1, Mariko Araki3.   

Abstract

BACKGROUND & AIMS: Osteoporosis is a chief complication in patients with anorexia nervosa. Serum levels of undercarboxylated osteocalcin reflect serum and bone vitamin K deficiency. We investigated vitamin K status in patients with anorexia nervosa to help establish prevention and treatment recommendations for osteoporosis.
METHODS: Fifty-four female amenorrheic patients with anorexia nervosa (29 restricting-type and 25 binge eating/purging type) (age, 28.0 (26.7-31.1) (mean (95% CI)) years; body mass index, 14.8 (14.1-15.5) kg/m(2), duration of illness; 107.3 (88.5-126.0) months) and 15 age-matched healthy females were included in this study. We measured serum levels of undercarboxylated osteocalcin, biochemical and nutritional markers, and bone metabolic markers. Dietary vitamin K intake was evaluated by a questionnaire.
RESULTS: Lumbar bone mineral density and T-scores in patients with anorexia nervosa were 0.756 (0.721-0.790) g/cm(2) and -2.4 (-2.1 to -2.7), respectively, indicating bone loss. Serum levels of undercarboxylated osteocalcin in patients with anorexia nervosa were significantly higher than those of controls. The 17% of restricting type and 40% of binge eating/purging type anorexia nervosa patients, serum levels of undercarboxylated osteocalcin were higher than 4.5 ng/ml and were diagnosed with vitamin K deficiency. Serum levels of undercarboxylated osteocalcin correlated significantly and negatively with vitamin K intake in patients with anorexia nervosa.
CONCLUSIONS: Patients with anorexia nervosa had vitamin K deficiency. Since a supplement of vitamin K might be effective for maintaining bone quality, we provide recommendations regarding vitamin K intake for prevention and treatment of osteoporosis in patients with AN.
Copyright © 2014 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Anorexia nervosa; Osteoporosis; Undercarboxylated osteocalcin; Vitamin K

Mesh:

Substances:

Year:  2014        PMID: 24909585     DOI: 10.1016/j.clnu.2014.04.016

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  6 in total

Review 1.  Eating disorders and bone metabolism in women.

Authors:  Lauren Robinson; Nadia Micali; Madhusmita Misra
Journal:  Curr Opin Pediatr       Date:  2017-08       Impact factor: 2.856

Review 2.  Pharmacological treatment options for low Bone Mineral Density and secondary osteoporosis in Anorexia Nervosa: A systematic review of the literature.

Authors:  Lauren Robinson; Victoria Aldridge; Emma M Clark; Madhusmita Misra; Nadia Micali
Journal:  J Psychosom Res       Date:  2017-05-12       Impact factor: 3.006

3.  Vitamin K homologs as potential biomarkers for disease activity in patients with rheumatoid arthritis.

Authors:  Hani M Khojah; Sameh Ahmed; Mahran S Abdel-Rahman; Khaled M Alkhalil; Al-Badr Hamza
Journal:  J Bone Miner Metab       Date:  2016-10-08       Impact factor: 2.626

4.  Evidence of a link between resting energy expenditure and bone remodelling, glucose homeostasis and adipokine variations in adolescent girls with anorexia nervosa.

Authors:  L Maïmoun; S Guillaume; P Lefebvre; P Philibert; H Bertet; M-C Picot; L Gaspari; F Paris; M Seneque; A-M Dupuys; P Courtet; E Thomas; D Mariano-Goulart; J Bringer; E Renard; C Sultan
Journal:  Osteoporos Int       Date:  2015-08-06       Impact factor: 4.507

5.  Vitamin K2 Prevents Glucocorticoid-induced Osteonecrosis of the Femoral Head in Rats.

Authors:  Yue-Lei Zhang; Jun-Hui Yin; Hao Ding; Wei Zhang; Chang-Qing Zhang; You-Shui Gao
Journal:  Int J Biol Sci       Date:  2016-01-28       Impact factor: 6.580

Review 6.  Role of Vitamin K in Intestinal Health.

Authors:  Yujiao Lai; Hori Masatoshi; Yanbo Ma; Yuming Guo; Bingkun Zhang
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.